Health ❯ Healthcare ❯ Patient Care

Treatment Protocols

Neoadjuvant Therapy Combination Therapies Adjuvant Therapy Combination Therapy Chemotherapy First-line Therapy Chemotherapy Regimens Intravenous Therapy Infusion Therapy Emergency Care Controlled Access Programs Supportive Medical Care Supportive Care Trauma Centers International Guidelines Clinical Trials Vepdegestrant Administration Adverse Events Contact Tracing Dosage Adjustment Data Management Maintenance Therapy Cognitive Impairment Lymphodepleting Chemotherapy Therapeutic Regimens Hemophilia Treatment Infection Risks Medication Tapering Adverse Effects Device Efficacy Antibiotic Treatment Medication Management Safety Profiles Medication Administration Antibiotic Management Clinical Guidelines Personalized Medicine Monitoring and Quarantine Event-Free Survival Surgical Interventions Randomized Trials Adjuvant Endocrine Therapy Clinical Trial Design Monitoring and Side Effects Antifungal Therapy Radiotherapy Sessions First-Line Therapy Medical Supervision Survival Rates Renin-Angiotensin System Therapy Treatment Algorithms Radiation Therapy Antibiotic Therapy First-Line Maintenance Therapy Smoking Cessation Programs Circadian Rhythms Infection Management Follow-up Care

Finerenone Slows Kidney Decline in Non‑Diabetic CKD, Trial Shows

Presented June 5, 2026, FIND‑CKD suggests finerenone could broaden treatment options for people with chronic kidney disease without diabetes.

Erleada Plus Hormone Therapy Cuts Recurrence and Death in High‑Risk Localized Prostate Cancer

Two-Session MRI-Guided Radiotherapy Matches Five Visits on Side Effects in Small Prostate Cancer Trial

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

FDA Approves Nivolumab Plus AVD as First-Line Therapy for Advanced Hodgkin Lymphoma

Tecvayli Cuts Progression Risk 71% and Deaths 40% in Phase 3 Myeloma Trial

Phase II Trial Finds 24 Gy Preoperative Radiation With Pembrolizumab Boosts T‑Cell Infiltration in HR+/HER2− Breast Cancer

Trial Finds Some Early Breast Cancer Patients Can Skip Sentinel Node Biopsy Without Harming 5-Year Control

Teclistamab–Daratumumab Delivers Major Survival Gains in Relapsed Myeloma, Phase 3 Data Show

Immunotherapy Before 3 p.m. Linked to Longer Survival in Small Cell Lung Cancer

Swedish Study Ties Lower Ipilimumab Dose to Longer Survival and Less Toxicity in Advanced Melanoma

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH

EndRAD Phase 2 Finds Non-TBI Conditioning Matches Outcomes in MRD-Negative Young B-ALL

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

FDA Approves Durvalumab Added to Perioperative FLOT for Resectable Gastric and GEJ Cancer

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit

Phase 3 Trial Finds Tukysa Improves PFS in First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC